European, Observational, Prospective Study to Evaluate the Benefit/Risk of Vandetanib in RET Mutation Negative and Positive Patients With Symptomatic, Aggressive, Sporadic, Unresectable, Locally Advanced/Metastatic Medullary Thyroid Cancer

Trial Profile

European, Observational, Prospective Study to Evaluate the Benefit/Risk of Vandetanib in RET Mutation Negative and Positive Patients With Symptomatic, Aggressive, Sporadic, Unresectable, Locally Advanced/Metastatic Medullary Thyroid Cancer

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Vandetanib (Primary)
  • Indications Thyroid cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Caprelsa104
  • Sponsors Sanofi Genzyme
  • Most Recent Events

    • 09 Feb 2016 Planned End Date changed from 1 Oct 2016 to 1 Sep 2019 as reported by ClinicalTrials.gov.
    • 09 Feb 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Sep 2019 as reported by ClinicalTrials.gov.
    • 09 Dec 2015 Planned End Date changed from 1 Oct 2018 to 1 Oct 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top